SecBot SecBot
SC 14D-9/A ·Filed Nov 12, 2026

PCRX

Pacira BioSciences, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4d 9h ago SEC0001140361-26-043433
Notable filing: SC 14D-9/A
Actionable Insight • Neutral

Monitor for any court rulings on preliminary injunctions that could delay or impose conditions on the tender offer closing by November 16. The volume of demand letters (15) suggests a coordinated plaintiff effort, but the board's stated intention to vigorously defend indicates no settlement is imminent.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$36.46
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.05%
T+1 · $36.48
Vs SPY
+1.97%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $36.46entry
  2. T+1 · 19h ago +0.05%α +1.97% · $36.48
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

Executive Summary

Pacira BioSciences filed Amendment No. 2 to its Schedule 14D-9, updating the legal proceedings section to disclose that two stockholder lawsuits and fifteen demand letters have been filed challenging the adequacy of disclosures in the merger with Viatris. The board continues to recommend the $36.50 per share tender offer, and the Pacira defendants intend to vigorously defend the actions.

Key Facts

  • Two stockholder complaints filed in New York state court alleging omitted or misrepresented material information in the Schedule 14D-9 regarding the merger
  • Fifteen demand letters received, including two draft complaints, seeking additional disclosure
  • Pacira defendants have not been served with the complaints
  • Board continues to recommend the $36.50 per share cash tender offer by Viatris
  • Tender offer expires November 16, 2026

Financial Impact

No financial impact stated; litigation seeks injunctive relief and damages if merger consummated, but outcome is uncertain

Risk Factors

  • Preliminary injunction could delay merger closing
  • Additional damages if merger consummated and plaintiffs prevail
  • Further complaints or demand letters may be filed

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 14D-9/A Filing (Primary)0001140361-26-043433
Document: 0001140361-26-043433-index-headers.html0001140361-26-043433
Document: 0001140361-26-043433-index.html0001140361-26-043433
Document: 0001140361-26-043433.txt0001140361-26-043433

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Viewing Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026